TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant

TAHO Pharmaceuticals Completes Pivotal Trial of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Jan. 21, 2025 /PRNewswire/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed discussions...

MicroAire Completes Acquisition of NEOSYAD

MicroAire Completes Acquisition of NEOSYAD

CHARLOTTESVILLE, Va., Jan. 21, 2025 /PRNewswire/ -- MicroAire Surgical Instruments, the global leader in power-assisted liposuction, is pleased to announce the acquisition of NEOSYAD, an innovative medical device company that developed a...

SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT

SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT

TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ -- Concept Medical Inc . (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with...

Spirit Advisors Client PicoCELA Inc completes its Nasdaq IPO

Spirit Advisors Client PicoCELA Inc completes its Nasdaq IPO

TOKYO and NEW YORK, Jan. 20, 2025 /PRNewswire/ -- Spirit Advisors LLC proudly announces the successful completion of the initial public offering (IPO) of PicoCELA Inc. (Nasdaq: PCLA), a pioneer in wireless communication technology. As the first...

Smartkem Completes First Sale of its TRUFLEX® Semiconductor Materials to Chip Foundation under their Co-Development Agreement

Smartkem Completes First Sale of its TRUFLEX® Semiconductor Materials to Chip Foundation under their Co-Development Agreement

Sales under the Chip Foundation co-development agreement are expected to continue throughout 2025 MANCHESTER, England, Jan. 16, 2025 /PRNewswire/ -- Smartkem (Nasdaq: SMTK), which is seeking to change the world of electronics using its disruptive...

Sygnum Completes USD 58m Strategic Growth Round, AchievesUnicorn Status with 1bn valuation

Sygnum Completes USD 58m Strategic Growth Round, AchievesUnicorn Status with 1bn valuation

ZURICH and SINGAPORE, Jan. 14, 2025 /PRNewswire/ -- Global digital asset banking group Sygnum announces it has raised a total of USD 58 million in its oversubscribed Strategic Growth Round, giving it a post-money valuation of more than 1 billion....

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /PRNewswire/ -- ZEISS...

Trillium Flow Technologies Successfully Completes Refinancing

Trillium Flow Technologies Successfully Completes Refinancing

STAMFORD, Conn., Jan. 13, 2025 /PRNewswire/ -- Trillium Flow Technologies ("Trillium"), a portfolio company of First Reserve, and a global designer, manufacturer, and aftermarket services provider of highly engineered valves and pumps used in...

Latest Updates of Viva Biotech's Portfolio Companies

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Jan. 8, 2025 /PRNewswire/ -- Recently, Viva Biotech's portfolio companies have new updates: TechnoDerma, VivaVision, Arthrosi, Apeiron Therapeutics and AceLink made solid progress in R&D; Full Circles published breakthrough results;...

Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis

Technoderma Medicines Completes Positive Ph2a Proof- of Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis

CHENGDU, China, Jan. 6, 2025 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935...

  • 1
  • 2
  • 3
  • 4
  • 5
  • menu
    menu